Article

Another application: Lens approved for therapy; CIBA helps fire victims

Atlanta-CIBA Vision's Focus Night & Day 30-day contact lenses will be marketed throughout Europe after receiving the CE Mark for therapeutic use.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
Related Content
FDA accepts new drug application for low-dose atropine from Sydnexis
March 11th 2025

FDA accepts new drug application for low-dose atropine from Sydnexis

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment
March 11th 2025

Renal dysfunction may affect intravitreal conbercept effectiveness in diabetic macular edema treatment

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain
March 10th 2025

OKYO Pharma files application for Fast Track designation with the FDA for urcosimod for the treatment of neuropathic corneal pain

Luxa Biotechnology presents clinical data from the phase 1/2a trial evaluating RPESC-RPE-4W
March 10th 2025

Luxa Biotechnology presents clinical data from the phase 1/2a trial evaluating RPESC-RPE-4W

© 2025 MJH Life Sciences

All rights reserved.